Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) CYR61 Antibodies:
anti-Human CYR61 Antibodies:
anti-Rat (Rattus) CYR61 Antibodies:
Go to our pre-filtered search.
Human Polyclonal CYR61 Primary Antibody for BP, ICC - ABIN151820
Gashaw, Stiller, Böing, Kimmig, Winterhager: Premenstrual regulation of the pro-angiogenic factor CYR61 in human endometrium. in Endocrinology 2008
Show all 7 Pubmed References
Human Polyclonal CYR61 Primary Antibody for ICC, IF - ABIN151821
Kurozumi, Hardcastle, Thakur, Shroll, Nowicki, Otsuki, Chiocca, Kaur: Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. in Molecular therapy : the journal of the American Society of Gene Therapy 2008
Show all 4 Pubmed References
Human Polyclonal CYR61 Primary Antibody for IHC, WB - ABIN223329
Mascareno, Galatioto, Rozenberg, Salciccioli, Kamran, Lazar, Liu, Pedrazzini, Siddiqui et al.: Cardiac lineage protein-1 (CLP-1) regulates cardiac remodeling via transcriptional modulation of diverse hypertrophic and fibrotic responses and angiotensin II-transforming growth factor ? (TGF-?1) ... in The Journal of biological chemistry 2012
Human Polyclonal CYR61 Primary Antibody for IHC, IHC (p) - ABIN4301817
Li, Pishdari, Cui, Hu, Yang, Guo, Jiang, Feng, Billig, Shao: Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome. in International journal of biological sciences 2015
Our results not only reveal a novel mechanism illustrating the role of Cyr61 in epidermis pathogenesis but also suggest that therapies targeting Cyr61 may represent a novel strategy in the treatment of psoriasis vulgaris.
The LPA1 (show LPAR1 Antibodies)-CCN1 (show CCNA2 Antibodies) axis may be the central control for SMC (show DYM Antibodies) migration.
these data suggest that the WNT (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) signaling pathway enhances pancreatic cancer development and malignancy in part via up-regulation of CYR61.
Lysophosphatidic acid induced time-dependent phosphorylation of serum response factor and CRE-binding protein in in smooth muscle cells, inducing transcription of CCN1.
Data show that Cysteine-rich 61 (CYR61) acts as a tumor-promoting gene in pancreatic neuroendocrine tumors.
CCN1 is an important regulator of chondrocyte maturation during cartilage development and homeostasis.
CCN1 exacerbates tracheal obliterative bronchiolitis by enhancing fibroproliferation via an alphavbeta3-integrin-independent pathway.
Data show that RNA silencing of CCN family member 1 protein (CCN1 (show CCNA2 Antibodies)) inhibits retinal neovascularization (RNV) by inhibiting phosphoinositide 3-kinase (PI3K)/AKT protein signaling in mouse pup model of oxyge (show AKT1 Antibodies)n-induced retinopathy (OIR).
These findings reveal a critical role for CCN1 in restoring mucosal homeostasis after intestinal injury
CCN1 (show CCNA2 Antibodies) is an injury response protein that functions not only to restrict fibrosis in the liver, but also to suppress hepatocarcinogenesis by inhibiting EGFR (show EGFR Antibodies)-dependent hepatocyte compensatory proliferation
The role of CYR61 in aromatase (show CYP19A1 Antibodies) inhibitors resistance in estrogen receptor (show ESR1 Antibodies) positive breast cancer patients
CYR61 is a TGF-beta (show TGFB1 Antibodies)-induced stromal-derived factor that regulates gemcitabine sensitivity in pancreatic ductal adenocarcinoma.
These studies support previously unrecognized, cooperative interaction between the CCN1 (show CCNA2 Antibodies) matricellular protein and canonical TGF-beta1 (show TGFB1 Antibodies)/SMAD3 (show SMAD3 Antibodies) signaling that promotes lung fibrosis.
Our data indicate a potential functional impact of Cyr61 in development and the progression of cervical cancer
results highlight both CYR61 and TAZ (show TAZ Antibodies) genes as potential predictive biomarkers for stratification of the risk for development of adenocarcinoma and suggest a potential mechanistic route for Barrett's esophagus neoplastic progression
Reduced levels of CCN1 (show CCNA2 Antibodies) and CCN3 (show NOV Antibodies), as found in early-onset preeclampsia, could contribute to a shift from invasive to proliferative extravillous trophoblasts and may explain their shallow invasion properties in this disease.
Promoter activity was determined as well as CYR61 mRNA and protein expression.
Results provide evidence that CCN1 can stimulate the proliferation and differentiation of osteoblasts in vitro and contribute to bone remodeling in vivo in myeloma bone disease.
The increased expression of CYR61 in the Day 4 corpus lutum (CL) and its transient increase by prostaglandin F2alpha in Day 6, Day 10, and Day 16 CL indicate that CYR61 may play a role in regulating angiogenesis over the life span of the CL.
Together, these results indicate that Cyr61 is an important determinant of the genetic reprogramming that occurs in mechanically challenged cells.
Mechanical regulation of the Cyr61 gene in smooth muscle cells
The secreted protein encoded by this gene is growth factor-inducible and promotes the adhesion of endothelial cells. The encoded protein interacts with several integrins and with heparan sulfate proteoglycan. This protein also plays a role in cell proliferation, differentiation, angiogenesis, apoptosis, and extracellular matrix formation.
cysteine-rich, angiogenic inducer, 61
, SMT3 suppressor of mif two 3 homolog 3
, small ubiquitin-related modifier 3
, protein CYR61-like
, CCN family member 1
, IGF-binding protein 10
, cysteine-rich angiogenic inducer 61
, insulin-like growth factor binding protein 10
, insulin-like growth factor-binding protein 10
, intermediate early
, protein CYR61
, cysteine-rich heparin-binding protein 61
, cysteine-rich, anigogenic inducer, 61
, cysteine rich protein 61
, secreted cysteine-rich protein cyr61